600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.
Trading 01-14 14:33:14
28.07
-0.11
-0.39%
High28.71Low27.76Vol34.68M
Open28.35D1 Closing28.18Amplitude3.37%
Mkt Cap74.95BTradable Cap59.45BTotal Shares2.67B
T/O983.00MT/O Rate1.64%Tradable Shares2.12B
P/B1.57ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application
MT Newswires Live  ·  01-08
Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application
BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules
Reuters  ·  01-08
BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules
Shanghai Fosun Pharma - Drug Registration Application of Foritinib Succinate Capsules Accepted by Nmpa
THOMSON REUTERS  ·  01-08
Shanghai Fosun Pharma - Drug Registration Application of Foritinib Succinate Capsules Accepted by Nmpa
Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted
Stock News  ·  01-08
Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted
Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing
MT Newswires Live  ·  01-06
Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing
Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical
Reuters  ·  2025-12-30
Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical
Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts
Deep News  ·  2025-12-23
Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts
Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?
Deep News  ·  2025-12-21
Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?
Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%
MT Newswires Live  ·  2025-12-19
Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%
Fosun United Health Insurance Withdraws Announcement of 9 Medical Insurance Plans Covering Innovative Drugs
Deep News  ·  2025-12-18
Fosun United Health Insurance Withdraws Announcement of 9 Medical Insurance Plans Covering Innovative Drugs
BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio
Reuters  ·  2025-12-18
BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio
Fosun Pharmaceutical Says Could Receive up to $362.5 Mln per Project IF Clavis Bio Exercises Option
THOMSON REUTERS  ·  2025-12-18
Fosun Pharmaceutical Says Could Receive up to $362.5 Mln per Project IF Clavis Bio Exercises Option
Fosun Pharmaceutical Says Unit Signs Deal With Clavis Bio for Co-Development and Exclusive Licensing Options
THOMSON REUTERS  ·  2025-12-18
Fosun Pharmaceutical Says Unit Signs Deal With Clavis Bio for Co-Development and Exclusive Licensing Options
FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio
Stock News  ·  2025-12-18
FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio
Fosun Pharma Acquires Green Valley Pharma: A Ray of Hope for Alzheimer's Patients?
Deep News  ·  2025-12-16
Fosun Pharma Acquires Green Valley Pharma: A Ray of Hope for Alzheimer's Patients?
BUZZ-Pfizer shares up ahead of co analyst and investor call Tuesday
Reuters  ·  2025-12-16
BUZZ-Pfizer shares up ahead of co analyst and investor call Tuesday
Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion
Reuters  ·  2025-12-15
Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion
Shanghai Fosun Pharmaceutical Says Unit Plans to Invest Total of 1.4 Bln Yuan to Acquire Controlling Stake in Pharmaceutical Firm
THOMSON REUTERS  ·  2025-12-15
Shanghai Fosun Pharmaceutical Says Unit Plans to Invest Total of 1.4 Bln Yuan to Acquire Controlling Stake in Pharmaceutical Firm
BRIEF-Shanghai Fosun Pharmaceutical's Unit Plans To Acquire Controlling Stake In Pharmaceutical Firm
Reuters  ·  2025-12-15
BRIEF-Shanghai Fosun Pharmaceutical's Unit Plans To Acquire Controlling Stake In Pharmaceutical Firm
Fosun Pharma Seeks Approval for New Indication of Cancer Drug
MT Newswires Live  ·  2025-12-15
Fosun Pharma Seeks Approval for New Indication of Cancer Drug

Introduction

Company Name.
上海复星医药(集团)股份有限公司
Industry:
医药制造业
Listing Date:
1998-08-07
Main Business:
　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
Issue price:
7.15